Among the available nonsurgical cosmetic procedures, body contouring treatments, and the use of injectables for aesthetic improvement, continue to gain popularity. As a modality for reducing unwanted adipose tissue, injection adipocytolysis, is an approach to body contouring that accommodates the growing patient inclination toward minimally invasive treatments.
ATX-101 injection (deoxycholic acid injection 10 mg/mL), from Allergan, Inc., known as Kybella in the U.S, and Belkyra in Canada, is the first FDA-approved pharmaceutical therapy for injection adipocytolysis.